Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

Thera4Care Theranostics Ecosystem for Personalised Care

Coordinator
Universita Cattolica Del Sacro Cuore, Italy
Runs
1 October 2024 to 30 September 2029
Status
Running
EU funding
€14.1m
Total cost
€25.3m
Partners
30 organisations in 15 countries
Type
Research and Innovation Action
Grant agreement
101172788

What the project is doing

In the project's own words, from its summary on CORDIS.

Thera4Care represents a large unique consortium, gathering well-established European academic radiotheranostic centres, strong industry partners, European and medical societies focusing on training and education, a patient advocacy group spearheaded by an experienced project management group. Thera4Care aims to establish a European network of radiotheranostics centres able to rapidly develop and implement radiotheranostics tools and solutions to drive precision health.

The overarching vision of Thera4Care is to revolutionise radiotheranostics procedures by establishing, implementing, and disseminating standardised scalable methods to produce and efficiently administer key radiotheranostics solutions. Thera4Care focus is on developing diagnostic and therapeutic ligands tailored to key disease areas (such as solid tumours), aligning with the growing significance of multi-modal radiotheranostics solutions dominated by radionuclide-based therapy and companion diagnostics.

Thera4Care project is scheduled for 5 years and consists of 9 work packages. WP1 handles Project Management, WP2 focuses on Regulatory aspects, WP3 plans Preclinical studies, WP4 provides Supply chain, WP5 develops Clinical Trials, WP6 generates AI models, WP7 focuses on Dosimetry, WP8 develops Precision Imaging components, while WP9 focuses on Education and Dissemination. Thera4Care will advocate for the progress of radiotheranostics, with the goal of increasing medical knowledge and enhancing treatment efficacy for improved patient outcomes.

Concurrently, aims to coordinate scientific initiatives across European landscapes, leveraging a comprehensive and multimodal approach to cancer therapy applicable to various cancer types. Lastly, will work on the establishment of sustainable supply and production networks and the upscaling of production methodologies and supply chains across the public and private sectors, to enhance the availability of radionuclides.

Topics

Who is involved

OrganisationCityCountryRole
Universita Cattolica Del Sacro CuoreMilanoItalyCoordinator
European Association of Nuclear MedicineWienAustriaParticipant
Association Hospitaliere De Bruxelles-Centre Hospitalier Universitaire Jules BordetAnderlechtBelgiumParticipant
Studiecentrum Voor Kernenergie / Centre D'etude De L'energie NucleaireBruxelles / BrusselBelgiumParticipant
The Oncidium FoundationBruxellesBelgiumParticipant
Paul Scherrer InstitutVilligen PsiSwitzerlandAssociatedpartner
Collaborate Project Management GmbHMunchenGermanyParticipant
Universitaetsklinikum EssenEssenGermanyParticipant
Curasight ASKobenhavnDenmarkParticipant
Minerva Imaging ApsOlstykkeDenmarkParticipant
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio MaranonMadridSpainThird party
Servicio Madrileno De SaludMadridSpainParticipant
Aiforia Technologies OyjHelsinkiFinlandParticipant
DosisoftCachanFranceParticipant
Institut De Cancerologie De L'ouestAngersFranceParticipant
Ge Healthcare Magyarorszag KftBudapestHungaryParticipant
Semmelweis EgyetemBudapestHungaryAssociatedpartner
Syreon Kutato Intezet Korlatolt Felelossegu TarsasagBudapestHungaryParticipant
Ge Medical Systems Israel LtdHaifaIsraelThird party
Datawizard SRLRomaItalyParticipant
Fondazione Policlinico Universitario Agostino Gemelli IrccsRomaItalyParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Terthera B.v.BredaNetherlandsParticipant
Atley Solutions ABGoteborgSwedenParticipant
Exini Diagnostics ABLundSwedenParticipant
Gems Pet Systems AktiebolagUppsalaSwedenThird party
Goeteborgs UniversitetGoeteborgSwedenParticipant
Ge Healthcare LimitedChalfont St GilesUnited KingdomAssociatedpartner
GE Healthcare IITS USA Corp.ChicagoUnited StatesAssociatedpartner
Perspective Therapeutics IncSeattleUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI